

Original Article

UV SPECTROPHOTOMETRIC AND RP- HPLC METHODS FOR SIMULTANEOUS ESTIMATION OF ISONIAZID, RIFAMPICIN AND PIPERINE IN PHARMACEUTICAL DOSAGE FORM

UMANG SHAH*¹, ANKITA JASANI¹

¹Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology, Charusat Campus, Changa 388421, Ta. Petlad, Dist. Anand, Gujarat, India
Email: umangshah.ph@charusat.ac.in

Received: 18 Aug 2014 Revised and Accepted: 21 Sep 2014

ABSTRACT

Objective: Simple, reliable, sensitive and accurate spectrophotometric and RP-HPLC methods for the estimation of INH, RIFA and PIPE in pure and pharmaceutical dosage form.

Methods: In the first Absorption correction method, methanol and distilled water were used as diluent. The wavelengths selected for the analysis were 262 nm, 338 nm and 477 nm for INH, PIPE and RIFA respectively. The Second RP - HPLC method has been developed using Acetonitrile as diluent. Successful separation of drugs was achieved on LC18 100 A⁰ column (250 x 4.6 mm, 5 μ) using 0.01M Sodium Dihydrogen Orthophosphate, pH 6.5 and acetonitrile (40:60, % v/v) as mobile phase with flow rate of 0.9 mL/min. The wavelength of detection was 282 nm. Validation of developed methods was done according to ICH Q2 (R1) guideline.

Results: Calibration curve was linear over the concentration range of 12-34.5 μg/mL (INH), 8-23 μg/mL (RIFA) and 0.4-1.15 μg/mL (PIPE) respectively for absorption correction method and 30- 330 μg/mL (INH), 20-220 μg/mL (RIFA) and 1-11 μg/mL (PIPE) for RP - HPLC method with r² value greater than 0.995. Accuracy of methods was determined by recovery studies and it was found to be 98 to 102 %. The % RSD values for all the validation parameters were less than 2.0 % for both the methods.

Conclusion: The developed RP-HPLC and UV spectrophotometric method were successfully applied for the quantitative determination of cited drugs in pharmaceutical dosage form.

Keywords: Isoniazid, Rifampicin, Piperine, UV- Spectrophotometry, RP-HPLC, Validation.

INTRODUCTION

Chemically, Isoniazid (INH) is pyridine-4-carbohydrazide. It is a hydrazide of isonicotinic acid and structure of INH are shown in Fig. 1 [1-2]. INH is official in Indian Pharmacopoeia, British Pharmacopoeia, United States Pharmacopoeia, Japanese Pharmacopoeia and European Pharmacopoeia [1-5]. INH is still considered the primary drug for the chemotherapy of tuberculosis. INH is bacteriostatic for "resting" bacilli, but is bactericidal for rapidly dividing microorganisms. INH is a prodrug; mycobacterial catalase-peroxidase converts INH into an active metabolite. A primary action of INH is to inhibit the biosynthesis of mycolic acids [6].

Chemically, Rifampicin (RIFA) is (12Z, 14E, 24E)- (2S, 16S, 17S, 18R, 19R, 20R, 21S, 22R, 23S) - 1,2 -dihydro- 5, 6, 9, 17, 19 -pentahydroxy, 23 -methoxy- 2, 4, 12, 16, 18, 20, 22 heptamethyl -8-(4-methylpiperazin -1 yliminomethyl) -1, 11 - dioxo 2, 7 (epoxy-pentadeca -1, 11, 13 trienimino) naphtha [2,1-b] furan -21-yl acetate and structure of RIFA is shown in Fig. 1 [7]. RIFA is official in Indian Pharmacopoeia, British Pharmacopoeia, United States Pharmacopoeia, Japanese Pharmacopoeia and European Pharmacopoeia [7-11]. Rifampicin acts by binding to and inhibiting DNA-dependent RNA polymerase in prokaryotic but not in eukaryotic cells. It is one of the most active anti-tuberculosis agents known, and is also effective against most gram-positive bacteria as well as many gram-negative species. It enters phagocytic cells and can therefore kill intracellular micro-organisms including the tubercle bacillus [12].

Chemically Piperine (PIPE) is 1-[5-(1, 3-benzodioxol-5-yl)-1-oxo-2, 4-pentadienyl] piperidine is a natural alkaloid use as bio enhancer and structure of PIPE is shown in Fig. 1. Piperine is official in IP 2010 [13].

Literature survey revealed that several methods were reported for the estimation of INH, RIFA and PIPE individually as well as in combination with some other drugs. Analytical methods reported

consisting of spectrophotometric [14-17], RP-HPLC [18-21], HPTLC [22-24], stability indicating HPLC [25], stability indicating HPTLC [26], LC-MS [27], LC-MS/MS [28], spectrofluorimetry [29]. As no method is reported for INH, RIFA and PIPE in combination. So, the aim of the present study was to develop accurate, precise and sensitive UV Spectrophotometric and RP - HPLC methods for the simultaneous estimation of INH, RIFA and PIPE in pure and in pharmaceutical dosage form and validate as per ICH Q2 (R1) guideline. Comparison of UV - spectrophotometric and RP - HPLC methods carried out by applying t-test to the assay results of all three drugs obtained by developed methods. So this study describes simple and sensitive spectrophotometric and chromatographic methods for determination of these drugs in pharmaceutical dosage form.




Fig. 1: Chemical structure of (a) INH (b) RIFA and (c) PIPE

MATERIALS AND METHODS

INH reference standard was gifted from Calyx Pharmaceutical Ltd., Mumbai and RIFA reference standard was gifted from Cadila Pharmaceutical Ltd., Gujarat. PIPE was purchased from Sigma Aldrich. Risorine capsule (300 mg INH, 200 mg RIFA and 10 mg PIPE) was procured from the local market. Analytical grade reagents

and solvents like methanol (AR), acetonitrile (HPLC grade), tri ethyl amine (TEA) and sodium dihydrogen orthophosphate were procured from Loba chemicals, Mumbai, India. Type I (HPLC grade) water was prepared by using the Millipore Milli-Q (DQ5) purification system.

Equipments instrumentation and software

UV-Visible double beam spectrophotometer with a matching pair of 1 cm quartz cuvettes (Shimadzu UV-1800, Shimadzu Corporation, Kyoto, Japan), connected to a computer loaded with Shimadzu UVPC version 3.42 software was used to record the absorption spectra of solutions. The spectral band width was 0.5 nm. An integrated HPLC system, LC 20AT from Shimadzu Corporation, Japan was used for the chromatographic separation of INH, RIFA and PIPE. The HPLC system was comprised of a binary gradient pump and manual sampler, column oven and a photodiode array detector. PC-installed LC solution software was used to record and integrate the chromatograms. Electronic weighing balance (Shimadzu AUX 220) was used for weighing the samples. Millipore Water purification system (DQ5) was used to get type I - HPLC grade water.

Spectrophotometric conditions for absorption correction method

Experimental condition

According to the solubility characteristics, the common solvent for the three drugs was found to be methanol. Hence the stock solution was prepared in methanol and further dilutions were made up with distilled water. The wavelengths selected for the analysis were 262 nm, 338 nm and 477 nm for INH, PIPE and RIFA, respectively.

Preparation of stock solutions

Accurately weighed and transferred 100 mg of INH, 100 mg of RIFA and 10 mg of PIPE working standard into a 100 mL amber color volumetric flasks respectively and 70 mL methanol was added. The mixture was sonicated for 10 min and diluted up to the mark with methanol. Final concentration of INH, RIFA and PIPE were 1000 µg/mL, 1000 µg/mL and 100 µg/mL respectively.

Construction of calibration curve

Aliquots (30, 20 and 10 mL) of INH, RIFA and PIPE from their stock solution respectively were transferred into 100 mL amber color volumetric flask and volume was made up to 100 mL with distilled water. From above solution aliquots of 0.4, 0.55, 0.7, 0.85, 1, 1.15 mL was taken and transferred into a 10 mL amber color volumetric flask and volume was made up to mark with distilled water to get a series of final concentration of INH (12-34.6 µg/mL), RIFA (8-23 µg/mL) and PIPE (0.4-1.15 µg/mL).

Analysis of marked formulation

Twenty capsules were accurately weighed and finely powdered. Capsule powder weight equivalent to 300 mg of INH, 200 mg of RIFA and 10 mg of PIPE accurately weighed and transferred to a 100 mL amber colored volumetric flask and 70 mL of methanol was added. The mixture was sonicated for 20 min and diluted up to the mark with methanol and filtered through a whatman filter paper no.41. From this solution 1 mL aliquot was withdrawn into a 10 mL amber colored volumetric flask and diluted up to the mark with distilled water. Solution contains 300 µg/mL of INH, 200 µg/mL of RIFA and 10 µg/mL of PIPE. From this solution 0.85 mL aliquot was withdrawn into 10 mL amber colored volumetric flask and diluted up to mark with water. So the solution contains INH (25.5 µg/mL), RIFA (17 µg/mL) and PIPE (0.85 µg/mL). The analysis procedure was repeated six times for the capsule formulation.

Chromatographic conditions

Experimental condition

The mobile phase consisted of buffer (0.01 M sodium dihydrogen orthophosphate) and acetonitrile in the ratio of 40:60 % v/v and pH adjusted to 6.5 with TEA. A membrane filter of 0.45 µm porosity was used to filter and degas the mobile phase was done by sonication. Separation was carried out on Phenomenex Luna HPLC analytical

C18 100 A⁰ column (250 x 4.6 mm, 5 µ) with isocratic elution. The flow rate was 0.9 mL/min and the detector was set at 282 nm. The volume of the sample solution injected was 20 µL. The analysis was carried out at 25 °C temperature.

Construction of calibration curve

Accurately weighed and transferred 300 mg, 200 mg and 10 mg of INH, RIFA and PIPE into 100 mL amber colored volumetric flask respectively and 70 mL acetonitrile was added. The mixture was sonicated for 20 min and diluted up to the mark with acetonitrile. Final concentration of INH, RIFA and PIPE were 1000 µg/mL, 1000 µg/mL and 100 µg/mL respectively. From above solution aliquots of 0.1, 0.3, 0.5, 0.7, 0.9 and 1.1 mL was taken and transfer in 10 mL amber color volumetric flask and volume was made up to mark with acetonitrile. So solution contains INH (30 - 330 µg/mL), RIFA (20-220 µg/mL) and PIPE (1-11 µg/mL).

Analysis of marked formulation

Twenty capsules were accurately weighed and finely powdered. Capsule powder weight equivalent to 300 mg of INH, 200 mg of RIFA and 10 mg of PIPE accurately weighed and transferred to a 100 mL amber colored volumetric flask and 70 mL of acetonitrile was added. The mixture was sonicated for 20 min and diluted up to the mark with methanol and filtered through a whatman filter paper no.41. From this solution 1 mL aliquot was withdrawn into 10 mL amber colored volumetric flask. Dilute it up to mark with acetonitrile. So the solution contains INH (150 µg/mL), RIFA (100 µg/mL) and PIPE (5 µg/mL). The analysis procedure was repeated six times for capsule formulation.

RESULTS AND DISCUSSION

Optimization of spectrophotometric conditions

The proposed method is based on spectrophotometric absorption correction method for the simultaneous estimation of INH, RIFA and PIPE in UV and Visible region using methanol and distilled water as solvents. The overlain spectra of INH, RIFA, PIPE and mixture are shown in Fig. 2.




Fig. 2: Overlain spectra of INH, RIFA, PIPE and mixture

The method is based upon direct estimation of RIFA at 477 nm, as at this wavelength INH and PIPE have zero absorbance and shows no interference. For estimation of PIPE, corrected absorbance was calculated at 338 nm due to the interference of RIFA and INH has zero absorbance at this wavelength. At 262 nm, these three drugs were shown absorbance. To estimate the amount of INH, the absorbance of RIFA and PIPE were corrected for interference at 262 nm by using their absorptivity values.

A set of three equations was framed using absorptivity coefficients at selected wavelengths.

$$C_x = \frac{A_1}{a_{x1}}$$

$$C_y = \frac{A_2 - a_{x2}C_x}{a_{y2}}$$

$$C_z = \frac{A_3 - (a_{x3}C_x + a_{y3}C_y)}{a_{z3}}$$

Where,

- A₁, A₂ and A₃ are absorbance of sample solution at 477 nm, 338 nm and 262 nm, respectively.
- a_{x1}, a_{x2} and a_{x3} are absorptivity coefficients of RIFA at 477 nm, 338 nm and 262 nm, respectively.
- a_{y2} and a_{y3} are absorptivity coefficients of PIPE at 338 nm and 262 nm, respectively.
- a_{z3} is absorptivity coefficients of INH at 262 nm.
- C_x, C_y and C_z are concentrations of RIFA, PIPE and INH respectively in the mixture. [30]

Optimization of chromatographic conditions

The main criterion for developing an RP-HPLC method was the determination of selected drugs in pharmaceutical dosage form in a single run, with emphasis on the method being accurate, reproducible, robust, linear, free of interference from other excipients and convenient enough for routine use in quality control laboratories.

The standard solution of INH, RIFA and PIPE were scanned over the range of 200 nm to 600 nm wavelengths. As shown in Fig. 2. the wavelength maxima of INH (261 nm), RIFA (477 nm) and PIPE (338 nm) are quite apart from each other and there was no isoblastic point was observed. Moreover, the combination has PIPE in lowest amount. So wavelength selected should be such that PIPE gives good response. Based on this, 282 nm was selected as detection wavelength. At 282 nm INH, RIFA and PIPE were showing quantifiable height and area.




Fig. 3: HPLC chromatogram of mixture (INH + RIFA + PIPE) in finally optimized conditions at 282 nm

Initially, the separation of all the peaks was studied by using a reversed-phase phenomenex L1 HPLC analytical C18 100 A⁰, 250 x 4.6 mm, 5 μ particle size columns with isocratic elution.

The mobile phase was selected on the basis of best resolution, peak purity index, peak symmetry and number of theoretical plates. Optimization of the mobile phase was performed based on trial and error method. In this method different mobile phase trials were tried in different buffer with differ in ratio and pH of the mobile phase. After that trial with buffer (0.01 M sodium dihydrogen orthophosphate): acetonitrile (40:60 % v/v) (pH 6.5), in this all three drugs are full fill all the criteria of system suitability test. So, finally buffer (0.01 M sodium dihydrogen orthophosphate): acetonitrile (40:60 % v/v) (pH 6.5) was selected as mobile phase.(Fig.3)

RIFA decomposes rapidly in acidic or alkaline conditions at 25 °C but slowly in neutral conditions so it is best to prepare aqueous solutions with oxygen-free solvent and at nearer to neutral pH.

Solution stability study

Solution stability was performed to check that the drugs were stable in solvent or not. The stability was performed by measuring the absorbance (for UV) and peak area (for HPLC) of the solution at different time intervals. It was observed that INH, RIFA and PIPE were stable in solution form upto 48 hours at refrigerated temperature.

Method validation

The developed and optimized method was validated for system suitability, specificity, sensitivity [limit of detection (LOD) & limit of quantitation (LOQ)], linearity, precision [repeatability & intermediate precision], accuracy and robustness as per ICH Q2 (R1) guideline [30-31].

System Suitability (for RP-HPLC)

System suitability is established to prove that suitability and reproducibility of the chromatographic system are adequate to perform an analysis. Single set of mixed standard solution was prepared as mentioned in the test method and six replicate injections of mixed standard preparation were injected and chromatogram was taken. Results were shown in Table 1.

Table 1: System suitability test parameters for INH, RIFA and PIPE by RP-HPLC method

Parameters	Drugs		
	INH	RIFA	PIPE
Retention time ^a	2.702	3.883	8.701
Tailing factor ^a	1.47	1.477	1.283
Theoretical plates ^a	4403.137	3350.974	12227.24
Resolution factor ^a	-	5.504	16.638
Peak area (% RSD) ^a	1.144	0.672	1.391

^a mean of 6 determinations

Specificity

The specificity of the method was determined by comparing the spectra (for UV) and chromatogram (for RP-HPLC) of the standard and sample solutions of INH, RIFA and PIPE. For HPLC peak purity index of each drug in the sample solution was found to be nearer to 1. Result obtained under optimized conditions has shown no interference from common capsule excipients and impurities. Result demonstrates the specificity of the method (Fig. 4a-4d).




Fig. 4a: Overlay spectra of blank, standard and sample solutions

Sensitivity

The sensitivity of the analytical method was evaluated by determining the limit of detection (LOD) and limit of quantification (LOQ) using following equations and result of sensitivity was shown in Table 2.

$$LOD = 3.3 \sigma / S \text{ and } LOQ = 10 \sigma / S$$

Where, σ = standard deviation of y intercept of calibration curve (n = 6)

S = slope of a regression equation.




Fig. 4b: Overlay chromatogram of standard and sample Solutions




Fig. 4c: Blank chromatogram of mobile phase




Fig. 4d: Peak purity of (a) INH (b) RIFA (c) PIPE

Table 2: LOD and LOQ for INH, RIFA and PIPE by proposed methods

Parameters	UV			HPLC		
	INH	PIPE	RIFA	INH	PIPE	RIFA
LOD (µg/mL)	0.318	0.054	0.971	3.015	2.289	0.11
LOQ (µg/mL)	0.965	0.164	2.942	9.135	6.936	0.332

Linearity

Linearity was checked by diluting standard stock solution at six different concentrations. The linear regression analysis obtained by

plotting the absorbance (for UV) and peak area (for HPLC) of analyte vs. concentration shown correlation coefficients(r^2) greater than 0.995. The statistical results such as correlation coefficient(r^2), slope and intercept are reported in Table 3.

Table 3: Linear regression data for calibration curve

Parameters	UV			HPLC		
	INH	RIFA	PIPE	INH	RIFA	PIPE
Concentration range (µg/mL)	12 - 34.6	8 - 23	0.4 - 1.15	30 - 330	20 - 220	1 - 11
Correlation coefficient (r^2) ^a	0.9979	0.9982	0.9981	0.9985	0.9987	0.9988
Intercept ^a	0.051	0.016	0.032	65379.16	80587.50	10560.33
Slope ^a	0.082	0.032	1.302	18616.83	22505.16	53693.33

^a mean of 6 determinations

Precision

The precision of the method was confirmed by repeatability and intermediate precision. Repeatability expresses the precision under the same operating conditions over a short interval of time.

The repeatability was performed by the analysis of the formulation was repeated for six times with the same concentration.

The amount of each drug present in the formulation was calculated as reported in % RSD. Result of repeatability was shown in Table 4.

Table 4: Result of repeatability study of INH, RIFA and PIPE

Parameters	UV			HPLC		
	INH	RIFA	PIPE	INH	RIFA	PIPE
Concentration (µg/mL)	25.5	17	0.85	150	100	5
SD ^a	0.272	0.09	0.001	1.586	1.295	0.027
% RSD ^a	1.024	0.511	0.505	1.015	1.208	0.5

^a mean of 6 determinations

The intermediate precision of the method was confirmed by intraday (variation of results within the same day) and interday (variation of results between days) analysis. The intraday and interday precision of the proposed methods were performed by analyzing the corresponding responses three times on the same day for intraday precision and over a period of three days for inter day

with three different concentrations of standard tertiary mixture solutions. The results were reported in terms of percentage of relative standard deviation (% RSD). Each concentration was applied in triplicates and % RSD was calculated. The precision studies data are represented in Table 5, 6 and 7 for INH, RIFA and PIPE, respectively.

Table 5: Results of intraday precision and interday precision studies of INH

Parameters	INH						
		UV			HPLC		
Concentration ($\mu\text{g/mL}$)		12	25.5	34.5	30	150	330
Intra-day precision	S. D ^a	0.16	0.21	0.54	0.477	1.606	2.41
	% RSD ^a	1.404	0.795	1.564	1.307	1.051	0.738
Inter-day precision	S. D ^a	0.181	0.917	0.576	0.575	1.69	2.922
	% RSD ^a	1.468	0.917	1.601	1.656	1.082	0.898

^a mean of 3 determinations

Table 6: Results of intraday precision and interday precision studies of RIFA

Parameters	RIFA						
		UV			HPLC		
Concentration ($\mu\text{g/mL}$)		8	17	23	20	100	220
Intra-day precision	S. D ^a	0.081	0.106	0.048	0.181	0.997	2.776
	% RSD ^a	1.015	0.106	0.205	0.822	0.943	1.186
Inter-day precision	S. D ^a	0.106	0.15	0.155	0.241	1.215	3.117
	% RSD ^a	1.329	0.865	0.651	1.076	1.159	1.356

^a mean of 3 determinations

Table 7: Results of intraday precision and interday precision studies of PIPE

Parameters	PIPE						
		UV			HPLC		
Concentration ($\mu\text{g/mL}$)		0.4	0.85	1.15	1	5	11
Intra-day precision	SD ^a	0.007	0.01	0.016	0.014	0.07	0.046
	% RSD ^a	1.645	1.129	1.388	1.187	1.387	0.395
Inter-day precision	SD ^a	0.007	0.012	0.017	0.017	0.079	0.124
	% RSD ^a	1.872	1.428	1.534	1.341	1.511	1.058

^a mean of 3 determinations

Table 8: Results of recovery studies of INH

Parameters	INH						
		UV			HPLC		
Level (%)		80	100	120	80	100	120
Sample Concentration ($\mu\text{g/mL}$)		12	12	12	150	150	150
Amount of Standard added ($\mu\text{g/mL}$)		9.6	12	14.4	120	150	180
Total Concentration ($\mu\text{g/mL}$)		21.6	24	26.4	270	300	330
Found Concentration ($\mu\text{g/mL}$) \pm SD ^a		21.273	23.553	26.014	272.148	294.503	325.316
		\pm 0.091	\pm 0.070	\pm 0.071	\pm 2.270	\pm 2.844	\pm 3.827
% RSD ^a		0.426	0.296	0.273	0.834	0.966	1.177
% Recovery ^a		98.5	98.14	98.54	100.81	98.17	98.59

^a mean of 3 determinations

Table 9: Results of recovery studies of RIFA

Parameters	RIFA						
		UV			HPLC		
Level (%)		80	100	120	80	100	120
Sample Concentration ($\mu\text{g/mL}$)		8	8	8	100	100	100
Amount of Standard added ($\mu\text{g/mL}$)		6.4	8	9.6	80	100	120
Total Concentration ($\mu\text{g/mL}$)		14.4	16	17.6	180	200	220
Found Concentration ($\mu\text{g/mL}$) \pm SD ^a		14.504	16.054	17.684	180.288 \pm 1.893	200.146	221.598
		\pm 0.034	\pm 0.039	\pm 0.035		\pm 0.748	\pm 2.773
% RSD ^a		0.236	0.242	0.197	1.05	0.374	1.251
% Recovery ^a		100.73	100.35	100.49	100.16	100.08	100.74

^a mean of 3 determinations

Table 10: Results of recovery studies of PIPE

Parameters	PIPE						
------------	------	--	--	--	--	--	--

	UV			HPLC		
	80	100	120	80	100	120
Level (%)	80	100	120	80	100	120
Sample Concentration ($\mu\text{g/mL}$)	0.4	0.4	0.4	5	5	5
Amount of Standard added ($\mu\text{g/mL}$)	0.32	0.4	0.48	4	5	6
Total Concentration ($\mu\text{g/mL}$)	0.72	0.8	0.88	9	10	11
Found Concentration ($\mu\text{g/mL}$) \pm SD ^a	0.728 \pm 0.009	0.786 \pm 0.007	0.876 \pm 0.015	8.828 \pm 0.093	9.825 \pm 0.082	11.068 \pm 0.088
% RSD ^a	1.271	0.885	1.711	1.05	0.838	0.794
% Recovery ^a	101.18	98.21	99.48	98.08	98.25	100.62

^a mean of 3 determinations

Accuracy

Accuracy of an analytical method is determined by the systemic error involved. It is the closeness of test results obtained by that method to the true value. The accuracy of the method was carried out at three levels 80, 100 and 120 % of the working concentration of sample. Calculated amount of standard solution of Rifampicin, Isoniazid and Piperine was spiked with added sample solution to prepare level 80, 100 and 120 % of the working concentration. From the total amount of drug found, the % recovery was calculated. This procedure was repeated for three times for each concentration. The % RSD was calculated. The results were shown in Table 8, 9 and 10.

Robustness (for RP-HPLC)

The robustness of an analytic procedure is a measure of its capacity to remain unaffected by small, but deliberate variation in method parameters and provides an indication of its reliability during normal usage. Robustness of the method was determined by small changes in flow rate, changes in pH, mobile phase ratio and wavelength of detection. Flow rate was changed to 0.9 ± 1.0 mL/min. The mobile phase ratio was changed to $\pm 2\%$ for all three components. Wavelength of detection was changed to 282 ± 2 nm. pH was changed ± 0.2 . The method was found to be robust with respect to variability in applied conditions. Result of robustness was shown in Table 11.

Table 11: Results of robustness study of INH, RIFA and PIPE

Chromatographic Parameter	Actual condition	Change condition	% RSD ^a		
			INH	RIFA	PIPE
pH \pm 0.2	6.5	6.3	0.808	0.491	1.131
		6.7	0.333	0.584	1.006
Flow rate \pm 10 %	0.9	0.8	0.535	0.539	1.035
		1	0.326	0.538	0.99
Wavelength \pm 2 nm	282	280	1.002	0.976	1.077
		284	0.969	0.959	0.965
Change in mobile phase ratio \pm 2 %	100%	98%	0.201	0.043	1.572
		102%	1.039	0.618	1.394

^amean of 3 determinations

Table 12: Results of assay in commercial sample

Parameters	UV			HPLC		
	INH	RIFA	PIPE	INH	RIFA	PIPE
Labeled Claim (mg)	300	200	10	300	200	10
% Assay \pm SD ^a	101.38 \pm 0.517	101.10 \pm 0.624	100.35 \pm 0.930	101.36 \pm 0.530	101.00 \pm 0.892	101.33 \pm 0.621
% RSD ^a	0.51	0.617	0.927	0.523	0.883	0.613

^amean of 6 determinations

Table 13: Results of t-test for INH, RIFA and PIPE

Parameter	INH		RIFA		PIPE	
	UV Method	RP -HPLC Method	UV Method	RP -HPLC Method	UV Method	RP -HPLC Method
Mean ^a	101.37	101.35	101.09	101.00	100.34	101.32
Variance ^a	0.267	0.281	0.389	0.795	0.864	0.385
Observations	6	6	6	6	6	6
Hypothesized Mean Difference	0		0		0	
d _f	5		5		5	
t _{stat}	0.183		0.158		-1.932	
P(T<=t) two-tail	0.862		0.881		0.111	
t _{critical} two-tail	2.571		2.571		2.571	

^amean of 6 assay determinations

Analysis of market formulation

The validated UV spectrophotometric and RP-HPLC methods were used in the analysis of the marketed formulation RISORINE with a label claim of 300 mg for INH, 200 mg for RIFA and 10 mg for PIPE per capsule. The results for the assay show good agreement with the label claims. Result of the assay was shown in Table 12.

Comparison of the UV Spectrophotometric and RP-HPLC Methods

The comparison of the developed UV spectrophotometric and RP-HPLC methods was carried out by applying t- test to the assay results of all three drugs obtained by developed methods. It was found that t_{stat} value was less than t_{critical} value for all the three drugs. Hence there was no significant difference between the developed methods. So both the developed methods can be successfully applied for quality control analysis of all three drugs in the combined pharmaceutical formulation. Result of statistical analytical comparison was shown in Table 13.

CONCLUSION

UV Spectrophotometric (Absorption correction method) and RP-HPLC methods were successfully developed and validated for the simultaneous determination of INH, RIFA and PIPE. The developed methods were found to be sensitive, accurate, precise, and robust. The results of the assay of the commercial formulation obtained from the UV and HPLC methods were not significantly different as per statistical analysis. This implies that the proposed UV and HPLC methods can be used for quality control analysis of INH, RIFA and PIPE in the combined pharmaceutical formulation.

CONFLICT OF INTERESTS

Declared None

ACKNOWLEDGEMENT

The authors thank to Calyx Pharmaceutical Ltd., and Cadila Pharmaceutical Ltd., for providing gift samples of INH and RIFA and Ramanbhai Patel College of Pharmacy (Charotar University of Science and Technology, Changa) for providing the necessary infrastructure to carry out the research.

REFERENCES

1. Japanese Pharmacopoeia, 16th edition. The ministry of Health, Labour and Welfare: Prefectural office in Japan; 2011. p. 985-7.
2. Indian Pharmacopoeia. Government of India Ministry of Health & Family Welfare: The Indian Pharmacopoeia Commission, Ghaziabad, India; 2007. p. 1515-7.
3. British Pharmacopoeia, Government of British: B. P Commission, Stationary Office; 2009:3259-61.
4. The United States Pharmacopoeia Drug Information. 18th edition. The United states Pharmacopoeia Convention: Inc. Rockville, Md, USA; 2007:2412-3.
5. European Pharmacopoeia: European Directorate for the Quality of medicines and healthcare; 2011. p. 2285-6.
6. Rang HP, Dale MM, Pitter JM, Flower RJJ. "RANG AND DALE'S Pharmacology". 6th edn. 2007. p. 675.
7. Indian Pharmacopoeia, Government of India Ministry of Health & Family Welfare: The Indian Pharmacopoeia Commission, Ghaziabad, India; 2007. p. 2054-9.
8. Japanese Pharmacopoeia, 16th edition. The ministry of Health, Labour and Welfare: Prefectural office in Japan: 2011. p. 1347-50.
9. British Pharmacopoeia, Government of British, B. P Commission: Stationary Office; 2009. p. 5206-9.
10. United States Pharmacopoeia, 18th edition. The United states Pharmacopoeia Convention: Inc. Rockville, Md, USA; 2007:3128-9.
11. European Pharmacopoeia: European Directorate for the Quality of medicines and healthcare; 2011:2856-7.
12. Hardman JG, Limbird LE, Alfred GG. "Goodman & Gilman's The Pharmacological Basis of Therapeutics", 10th edn; 2006. p. 1273.
13. Indian Pharmacopoeia, Government of India Ministry of Health & Family Welfare: The Indian Pharmacopoeia Commission, Ghaziabad, India; 2010. p. 2522-3.
14. Manna A, Datta S, Ghosh PK, Ghosh LK, Gupta BK. Simultaneous estimation of Isoniazid and Rifampicin in combine dosage form. Indian J Pharm Sci 2000;62(3):185-6.
15. Sharma SC, Das S, Talwar SK. Spectrophotometric estimation of Rifampin-Isoniazid mixture in dosage form. J Asso Anal Chem 1987;70(04):679-81.
16. Gupta V, Jain UK. Quantitative analysis of piperine in ayurvedic formulation by UV Spectrophotometry. Inter J Pharm Sci Res 2011;2(02):58-61.
17. Gupta V, Jain UK. Estimation of Piperine by UV-Spectrophotometric method in herbal formulation *Pippli Churna*. Inter J Res Pharm Biomed Sci 2011;2(02):550-3.
18. Shyam PT, Rao Y, Chaithanya Y, Raghavendhra P, Surendar M, Banji D. Method development and validation of RP-HPLC method for simultaneous estimation of Rifampicin, Isoniazid & Pyridoxine hydrochloride in bulk pharmaceutical dosage form. Int J Pharm Res Development 2012;4(08):153-62.
19. Solanki SS, Bhadoriya U, Jain S, Dhanwani RK, Kumar S. Quantitative analysis of Piperine in an ayurvedic formulation using reverse phase high performance liquid chromatography. Asian J Pharm Med Sci 2012;2(01):11-5.
20. Calleja I, Blanco-Príeto MJ, Ruz N, Renedo MJ, Dios-Viéitez MC. High-performance liquid-chromatographic determination of Rifampicin in plasma and tissues. J Chrom A 2004;1031(1):289-94.
21. Mariappan TT, Singh B, Singh S. A validated Reversed-Phase (C18) HPLC Method for simultaneous determination of rifampicin, isoniazid and pyrazinamide in USP dissolution medium and simulated gastric fluid. Pharm Pharmacol Communications 2000;6(8):345-9.
22. Vyas N, Gamit K, Khan MY, Panchal S, Pundarikakshudu K. Simultaneous estimation of Curcumin and Piperine in their crude powder mixture and ayurvedic formulation using high performance thin layer chromatography. Int J Res Pharm Biomed Sci 2011;2(01):231-6.
23. Tapadiya G, Metku M, Deokate U, Khadabadi S, Saboo S, Sahu K. Quantitative estimation of Piperine from pharmaceutical dosage form by HPTLC. Asian J Pharm Clin Res 2009;2(02):47-50.
24. Shanmugasundaram P, Maheswari R, Vijayaanandhi M. Quantitative estimation of Piperine in herbal cough syrup by HPTLC method. Rasayan J Chem 2008;1(02):212-7.
25. Glass BD, Kustrin SA, Chen YJ, Wisch MH. Optimization of a stability-indicating HPLC method for the simultaneous determination of Rifampicin, Isoniazid and Pyrazinamide in a fixed-dose combination using artificial neural networks. J Chromatographic Sci 2007;45:38-44.
26. Ali J, Sultana Y, Baboota S, Faiyaz S. Development and validation of a stability-indicating HPTLC method for analysis of antitubercular drugs. Acta Chromatographica 2007;18:168-79.
27. Patil JS, Sarasija S, Sureshbabu AR, Rajesh MS. Development and validation of liquid chromatography-mass spectrometry method for the estimation of Rifampicin in plasma. Indian J Pharm Sci 2011;73(05):558-63.
28. Srivastava A, Waterhouse D, Ardrey A, Ward SA. Quantification of rifampicin in human plasma and cerebrospinal fluid by a highly sensitive and rapid liquid chromatographic-tandem mass spectrometric method. J Pharm Biomed Anal 2012;70:523-8.
29. Patel S, Vyas N. Validated spectrofluorimetric method for estimation of piperine in an ayurvedic formulation. Asian J Pharm Clin Res 2012;5(04):231-3.
30. ICH-Q2 (R1), Guidance on validation of analytical procedure: text and methodology. The European Agency for the evaluation of medicinal products, Geneva, Switaerland: 2005.
31. Anandakumar K, Jayamariappan M. Absorption correction method for the simultaneous estimation of Amlodipine besylate, Valsartan and Hydrochlorothiazide in bulk and in combined tablet dosage form. Int J Pharm Pharm Sci 2011;3(01):23-7.